🇺🇸 FDA
Patent

US 9861681

Therapeutic compositions for neutralizing type I interferons, and methods of use

granted A61KA61K38/162A61P

Quick answer

US patent 9861681 (Therapeutic compositions for neutralizing type I interferons, and methods of use) held by The United States of America as represented by the Secretary of the Army, on behalf of the United States Army Medical Research Institute of Infectious Diseases expires Mon Jan 04 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America as represented by the Secretary of the Army, on behalf of the United States Army Medical Research Institute of Infectious Diseases
Grant date
Tue Jan 09 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 04 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
13
CPC classes
A61K, A61K38/162, A61P, A61P31/12, A61P37/06